Clarithromycin prevents smoke-induced emphysema in mice

American Journal of Respiratory and Critical Care Medicine

Volumn 179, Issue 4, 2009, Pages 271-278

  Nakanishi, Yutaka ^a,b   Kobayashi, Dale ^c   Asano, Yasuo ^a   Sakurai, Takanobu ^a   Kashimura, Masato ^a   Okuyama, Shigeru ^a   Yoneda, Yukio ^b   Shapiro, Steven D ^d   Takayama, Kiyoshi ^a,e  

^a TAISHO PHARMACEUTICAL CO LTD   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c WASHINGTON UNIVERSITY   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e Research Center   (Japan)

Author keywords

Anti Inflammatory agents; Chronic obstructive pulmonary disease; Macrolides

Indexed keywords

CIGARETTE SMOKE; CLARITHROMYCIN; TUMOR NECROSIS FACTOR ALPHA; ANTIINFECTIVE AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CIGARETTE SMOKING; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HISTOPATHOLOGY; IMMUNOHISTOLOGY; LUNG ALVEOLUS WALL; LUNG COMPLIANCE; LUNG EMPHYSEMA; LUNG LAVAGE; LUNG PARENCHYMA; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PROPHYLAXIS; ANIMAL; AREA UNDER THE CURVE; C57BL MOUSE; DISEASE MODEL; DOSE RESPONSE; EMPHYSEMA; ENVIRONMENTAL EXPOSURE; FLUORESCENT ANTIBODY TECHNIQUE; IN VITRO STUDY; LUNG; MACROPHAGE; METHODOLOGY; PASSIVE SMOKING; POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

ANIMALS; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BRONCHOALVEOLAR LAVAGE FLUID; CLARITHROMYCIN; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EMPHYSEMA; ENVIRONMENTAL EXPOSURE; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; LUNG; LUNG COMPLIANCE; MACROPHAGES; MICE; MICE, INBRED C57BL; POLYMERASE CHAIN REACTION; TOBACCO SMOKE POLLUTION; TREATMENT OUTCOME;

EID: 60749133504     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200806-905OC     Document Type: Article

References (41)

1. Peto R, Chen ZM, Boreham J. Tobacco: the growing epidemic. Nat Med 1999;5:15-17.
2. Fukuchi Y, Nishimura M, Ichinose M, Adachi M, Nagai A, Kuriyama T, Takahashi K, Nishimura K, Ishioka S, Aizawa H, et al. COPD in Japan: the Nippon COPD Epidemiology study. Respirology 2004;9: 458-465.
3. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 2003;22: 672-688.
4. Chung KF. Inflammatory mediators in chronic obstructive pulmonary disease. Curr Drug Targets Inflamm Allergy 2005;4:619-625.
5. Muroski ME, Roycik MD, Newcomer RG, Van den Steen PE, Opdenakker G, Monroe HR, Sahab ZJ, Sang QX. Matrix metallo- proteinase-9/gelatinase B is a putative therapeutic target of chronic obstructive pulmonary disease and multiple sclerosis. Curr Pharm Biotechnol 2008;9:34-46.
6. Churg A, Wang R, Wang X, Onnervik PO, Thim K, Wright JL. Effect of an MMP-9/MMP-12 inhibitor on smoke-induced emphysema and airway remodelling in guinea pigs. Thorax 2007;62:706-713.
7. Pemberton PA, Cantwell JS, Kim KM, Sundin DJ, Kobayashi D, Fink JB, Shapiro SD, Barr PJ. An inhaled matrix metalloprotease inhibitor prevents cigarette smoke-induced emphysema in the mouse. COPD 2005;2:303-310.
8. Molet S, Belleguic C, Lena H, Germain N, Bertrand CP, Shapiro SD, Planquois JM, Delaval P, Lagente V. Increase in macrophage elastase (MMP-12) in lungs from patients with chronic obstructive pulmonary disease. Inflamm Res 2005;54:31-36.
9. Shapiro SD, Goldstein NM, Houghton AM, Kobayashi DK, Kelley D, Belaaouaj A. Neutrophil elastase contributes to cigarette smoke- induced emphysema in mice. Am J Pathol 2003;163:2329-2335.
10. Gamble E, Grootendorst DC, Brightling CE, Troy S, Qiu Y, Zhu J, Parker D, Matin D, Majumdar S, Vignola AM, et al. Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003;168:976-982.
11. Grootendorst DC, Gauw SA, Verhoosel RM, Sterk PJ, Hospers JJ, Bredenbroker D, Bethke TD, Hiemstra PS, Rabe KF. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax 2007;62:1081-1087.
12. Giembycz MA. An update and appraisal of the cilomilast Phase III clinical development programme for chronic obstructive pulmonary disease. Br J Clin Pharmacol 2006;62:138-152.
13. Chung KF. Cytokines as targets in chronic obstructive pulmonary disease. Curr Drug Targets 2006;7:675-681.
14. Barnes PJ, Hansel TT. Prospects for new drugs for chronic obstructive pulmonary disease. Lancet 2004;364:985-996.
15. Montuschi P, Macagno F, Parente P, Valente S, Lauriola L, Ciappi G, Kharitonov SA, Barnes PJ, Ciabattoni G. Effects of cyclo-oxygenase inhibition on exhaled eicosanoids in patients with COPD. Thorax 2005;60:827-833.
16. Mahler DA, Huang S, Tabrizi M, Bell GM. Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study. Chest 2004;126:926-934.
17. Gompertz S, Stockley RA. A randomized, placebo-controlled trial of a leukotriene synthesis inhibitor in patients with COPD. Chest 2002; 122:289-294.
18. Shinkai M, Foster GH, Rubin BK. Macrolide antibiotics modulate ERK phosphorylation and IL-8 and GM-CSF production by human bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol 2006;290: L75-L85.
19. Suzuki T, Yamaya M, Sekizawa K, Hosoda M, Yamada N, Ishizuka S, Yoshino A, Yasuda H, Takahashi H, Nishimura H, et al. Erythromycin inhibits rhinovirus infection in cultured human tracheal epithelial cells. Am J Respir Crit Care Med 2002;165:1113-1118.
20. Oda H, Kadota J, Kohno S, Hara K. Leukotriene B4 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis. Chest 1995;108: 116-122.
21. Kudoh S, Azuma A, Yamamoto M, Izumi T, Ando M. Improvement of survival in patients with diffuse panbronchiolitis treated with low- dose erythromycin. Am J Respir Crit Care Med 1998;157:1829-1832.
22. Hautamaki RD, Kobayashi DK, Senior RM, Shapiro SD. Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science 1997;277:2002-2004.
23. D'hulst AI, Maes T, Bracke KR, Demedts IK, Tournoy KG, Joos GF, Brusselle GG. Cigarette smoke-induced pulmonary emphysema in scid- mice. Is the acquired immune system required? Respir Res 2005;6:147-159.
24. Suzuki T, Yanai M, Yamaya M, Satoh-Nakagawa T, Sekizawa K, Ishida S, Sasaki H. Erythromycin and common cold in COPD. Chest 2001; 120:730-733.
25. Kohno S, Koga H, Yamaguchi K, Masaki M, Inoue Y, Dotsu Y, Masuyama Y, Hayashi T, Hirota M, Saito A, et al. A new macrolide, TE-031 (A-56268), in treatment of experimental Legionnaires' disease. J Antimicrob Chemother 1989;24:397-405.
26. Hand WL, Corwin RW, Steinberg TH, Grossman GD. Uptake of antibiotics by human alveolar macrophages. Am Rev Respir Dis 1984;129:933-937.
27. Kaneko Y, Yanagihara K, Seki M, Kuroki M, Miyazaki Y, Hirakata Y, Mukae H, Tomono K, Kadota J, Kohno S. Clarithromycin inhibits overproduction of muc5ac core protein in murine model of diffuse panbronchiolitis. Am J Physiol Lung Cell Mol Physiol 2003;285:L847-L853.
28. Iino Y, Toriyama M, Kudo K, Natori Y, You A. Erythromycin inhibition of lipopolysaccharide-stimulated tumor necrosis factor alpha production by human monocytes in vitro. Ann Otol Rhinol Laryngol Suppl 1992;157:16-20.
29. Takeshita K, Yamagishi I, Harada M, Otomo S, Nakagawa T, Mizushima Y. Immunological and anti-inflammatory effects of clarithromycin: inhibition of interleukin 1 production of murine peritoneal macrophages. Drugs Exp Clin Res 1989;15:527-533.
30. Kikuchi T, Hagiwara K, Honda Y, Gomi K, Kobayashi T, Takahashi H, Tokue Y, Watanabe A, Nukiwa T. Clarithromycin suppresses lipopoly- saccharide-induced interleukin-8 production by human monocytes through AP-1 and NF-kappa B transcription factors. J Antimicrob Chemother 2002;49:745-755.
31. Ichiyama T, Nishikawa M, Yoshitomi T, Hasegawa S, Matsubara T, Hayashi T, Furukawa S. Clarithromycin inhibits NF-kappaB activation in human peripheral blood mononuclear cells and pulmonary epithelial cells. Antimicrob Agents Chemother 2001;45:44-47.
32. Abe S, Nakamura H, Inoue S, Takeda H, Saito H, Kato S, Mukaida N, Matsushima K, Tomoike H. Interleukin-8 gene repression by clarithromycin is mediated by the activator protein-1 binding site in human bronchial epithelial cells. Am J Respir Cell Mol Biol 2000;22:51-60.
33. Houghton AM, Quintero PA, Perkins DL, Kobayashi DK, Kelley DG, Marconcini LA, Mecham RP, Senior RM, Shapiro SD. Elastin fragments drive disease progression in a murine model of emphysema. J Clin Invest 2006;116:753-759.
34. Wu L, Fan J, Matsumoto S, Watanabe T. Induction and regulation of matrix metalloproteinase-12 by cytokines and CD40 signaling in monocyte/macrophages. Biochem Biophys Res Commun 2000;269:808-815.
35. Xie S, Issa R, Sukkar MB, Oltmanns U, Bhavsar PK, Papi A, Caramori G, Adcock I, Chung KF. Induction and regulation of matrix metal-loproteinase-12 in human airway smooth muscle cells. Respir Res 2005;6:148.
36. Churg A, Wang RD, Tai H, Wang X, Xie C, Wright JL. Tumor necrosis factor-alpha drives 70% of cigarette smoke-induced emphysema in the mouse. Am J Respir Crit Care Med 2004;170:492-498.
37. Jovanovic DV, Martel-Pelletier J, Di Battista JA, Mineau F, Jolicoeur FC, Benderdour M, Pelletier JP. Stimulation of 92-kd gelatinase (matrix metalloproteinase 9) production by interleukin-17 in human monocyte/macrophages: a possible role in rheumatoid arthritis. Arthritis Rheum 2000;43:1134-1144.
38. Woo CH, Lim JH, Kim JH. Lipopolysaccharide induces matrix metal-loproteinase-9 expression via a mitochondrial reactive oxygen spe-cies-p38 kinase-activator protein-1 pathway in Raw 264.7 cells. J Immunol 2004;173:6973-6980.
39. Simpson JL, Powell H, Boyle MJ, Scott RJ, Gibson PG. Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med 2008;177:148-155.
40. Banerjee D, Honeybourne D, Khair OA. The effect of oral clarithromycin on bronchial airway inflammation in moderate-to-severe stable COPD: a randomized controlled trial. Treat Respir Med 2004;3:59-65.
41. Li YJ, Azuma A, Usuki J, Abe S, Matsuda K, Sunazuka T, Shimizu T, Hirata Y, Inagaki H, Kawada T, et al. EM703 improves bleomycin- induced pulmonary fibrosis in mice by the inhibition of TGF-beta signaling in lung fibroblasts. Respir Res 2006;7:16.